Bamlanivimab injection is used to treat COVID-19 infection in certain non-hospitalized adults and children 12 years of age and older who weigh at least 88 pounds (40 kg) and who have mild to moderate COVID-19 symptoms. It is used in people who have certain medical conditions that make them at higher risk for developing severe COVID-19 symptoms or the need to be hospitalized from COVID-19 infection. Bamlanivimab is in a class of medications called monoclonal antibodies. It works by blocking the action of a certain natural substance in the body to stop the spread of the virus.
Bamlanivimab and Etesevimab Injection
Bamlanivimab and etesevimab injection is used in certain non-hospitalized adults, children, and infants including newborns, and who have certain medical conditions that make them at higher risk for developing severe COVID-19 symptoms, including hospitalization or death: to treat mild to moderate symptoms of COVID-19. to prevent COVID-19 in those who are not fully vaccinated against COVID-19 or who are vaccinated, but have a weakened immune system, or are taking a medication that affects the immune system and who have had close contact or are at high risk of close contact to someone who is infected with the SARS-CoV-2 virus (for example, nursing homes, prisons). Bamlanivimab and etesevimab is also used to treat mild to moderate symptoms of COVID-19 in hospitalized children and infants less than 2 years of age, including newborns. Bamlanivimab and etesevimab are in a class called monoclonal antibodies. These medications work by blocking the action of a certain natural substance in the body to stop the spread of the virus.
* Please review the disclaimer below.
 What is the Non-Proprietary Name? - The non-proprietary name is sometimes called the generic name. The generic name usually includes the active ingredient(s) of the product.
 What is the Substance Name? - An active ingredient is the substance responsible for the medicinal effects of a product specified by the substance's molecular structure or if the molecular structure is not known, defined by an unambiguous definition that identifies the substance. Each active ingredient name is the preferred term of the UNII code submitted.
 What kind of product is this? - Indicates the type of product, such as Human Prescription Drug or Human Over the Counter Drug. This data element matches the “Document Type” field of the Structured Product Listing.
 What are the Administration Routes? - The translation of the route code submitted by the firm, indicating route of administration.
 What is the Labeler Name? - Name of Company corresponding to the labeler code segment of the Product NDC.
 What is the Marketing Category? - Product types are broken down into several potential Marketing Categories, such as NDA/ANDA/BLA, OTC Monograph, or Unapproved Drug. One and only one Marketing Category may be chosen for a product, not all marketing categories are available to all product types. Currently, only final marketed product categories are included. The complete list of codes and translations can be found at www.fda.gov/edrls under Structured Product Labeling Resources.
 What is the Start Marketing Date? - This is the date that the labeler indicates was the start of its marketing of the drug product.
 What is the Listing Expiration Date? - This is the date when the listing record will expire if not updated or certified by the product labeler.
 What is the NDC Exclude Flag? - This field indicates whether the product has been removed/excluded from the NDC Directory for failure to respond to FDA"s requests for correction to deficient or non-compliant submissions ("Y"), or because the listing certification is expired ("E"), or because the listing data was inactivated by FDA ("I"). Values = "Y", "N", "E", or "I".